ozenoxacin and Multiple-Myeloma

ozenoxacin has been researched along with Multiple-Myeloma* in 1 studies

Other Studies

1 other study(ies) available for ozenoxacin and Multiple-Myeloma

Article	Year
Identification of Trovafloxacin, Ozanimod, and Ozenoxacin as Potent c-Myc G-Quadruplex Stabilizers to Suppress c-Myc Transcription and Myeloma Growth. Molecular informatics, 2022, Volume: 41, Issue:10 c-Myc is a major oncogene that is estimated to result in almost all human cancers and the c-Myc downregulation has become an attractive strategy for cancer treatment. For it is hard to design compounds that can directly interact with the c-Myc protein, the DNA G-quadruplex (G4) was discovered in its promoter region which was referred to as a potential drug target for controlling c-Myc expression. In this study, a combined strategy of molecular docking-based virtual screening, molecular dynamics (MD) simulation, and molecular mechanics/generalized Born surface area (MM/GBSA) free energy calculation was conducted on the existing FDA-Approved Drugs Library, eight compounds were selected for further experimental assay. Among them, five compounds exhibited dose-dependently anticancer activities against RPMI-8226 cells with IC Topics: Aminopyridines; DNA; Fluoroquinolones; Humans; Indans; Molecular Docking Simulation; Multiple Myeloma; Naphthyridines; Oxadiazoles; Quinolones; RNA, Messenger	2022

Article

Year

Identification of Trovafloxacin, Ozanimod, and Ozenoxacin as Potent c-Myc G-Quadruplex Stabilizers to Suppress c-Myc Transcription and Myeloma Growth.

Molecular informatics, 2022, Volume: 41, Issue:10

c-Myc is a major oncogene that is estimated to result in almost all human cancers and the c-Myc downregulation has become an attractive strategy for cancer treatment. For it is hard to design compounds that can directly interact with the c-Myc protein, the DNA G-quadruplex (G4) was discovered in its promoter region which was referred to as a potential drug target for controlling c-Myc expression. In this study, a combined strategy of molecular docking-based virtual screening, molecular dynamics (MD) simulation, and molecular mechanics/generalized Born surface area (MM/GBSA) free energy calculation was conducted on the existing FDA-Approved Drugs Library, eight compounds were selected for further experimental assay. Among them, five compounds exhibited dose-dependently anticancer activities against RPMI-8226 cells with IC

Topics: Aminopyridines; DNA; Fluoroquinolones; Humans; Indans; Molecular Docking Simulation; Multiple Myeloma; Naphthyridines; Oxadiazoles; Quinolones; RNA, Messenger

2022